Schedule 13G ownership disclosure

ADAPTIMMUNE THERAPEUTICS PLC

American Depositary Shares, each representing 6 Ordinary Shares · CUSIP: 00653A107

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • LONG FOCUS CAPITAL MANAGEMENT, LLC

    Shares: 20,494,393.00 · Class: 8.0%

  • LONG FOCUS CAPITAL MASTER, LTD.

    Shares: 13,354,858.00 · Class: 5.2%

  • CONDAGUA, LLC

    Shares: 7,139,535.00 · Class: 2.8%

  • JOHN HELMERS

    Shares: 20,494,393.00 · Class: 8.0%

  • GLENN HELMERS

    Shares: 7,139,535.00 · Class: 2.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001019056-25-000075
Form type
SCHEDULE 13G/A
Filer
Adaptimmune Therapeutics PLC
CIK
CIK 1621227
Filed
Feb 11, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub